(Q38584890)

English

Safety and tolerability of antidepressant co-treatment in acute major depressive disorder: results from a systematic review and exploratory meta-analysis

scientific article published on 10 September 2015

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

0 references

Safety and tolerability of antidepressant co-treatment in acute major depressive disorder: results from a systematic review and exploratory meta-analysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

major depressive disorder

1 reference

based on heuristic

inferred from title

Christoph Correll

6

object named as

Christoph U Correll

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

author name string

Britta Galling

1

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Amat Calsina Ferrer

2

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Margarita Abi Zeid Daou

3

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Dinesh Sangroula

4

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Katsuhiko Hagi

5

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

language of work or name

0 references

publication date

10 September 2015

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Expert Opinion on Drug Safety

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

1587-1608

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

Antidepressants in clinical practice: limitations of assessment methods and drug response

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1085970

21 January 2018

Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1085970

21 January 2018

What Happened to Lithium? Antidepressant Augmentation in Clinical Settings

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1085970

21 January 2018

Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1085970

21 January 2018

Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1085970

21 January 2018

Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1085970

21 January 2018

Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1085970

21 January 2018

To combine or not to combine? A literature review of antidepressant combination therapy

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1085970

21 January 2018

Evidence for the benefits of nonantipsychotic pharmacological augmentation in the treatment of depression

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1085970

21 January 2018

Use of antidepressant combinations: which, when and why? Results of a Spanish survey

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1085970

21 January 2018

Which factors influence psychiatrists' selection of antidepressants?

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1085970

21 January 2018

Combination of antidepressants in the treatment of major depressive disorder: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1085970

21 January 2018

Antidepressant combination for major depression in incomplete responders--a systematic review

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1085970

21 January 2018

If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1085970

21 January 2018

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1085970

21 January 2018

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1085970

21 January 2018

A double-blind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1085970

21 January 2018

Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1085970

21 January 2018

Morning fluoxetine plus evening mianserin versus morning fluoxetine plus evening placebo in the acute treatment of major depression.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1085970

21 January 2018

Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1085970

21 January 2018

Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1085970

21 January 2018

Duloxetine-bupropion combination for treatment-resistant atypical depression: a double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1085970

21 January 2018

Treatment strategies in patients with major depression not responding to first-line sertraline treatment. A randomised study of extended duration of treatment, dose increase or mianserin augmentation

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1085970

21 January 2018

Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1085970

21 January 2018

Efficacy and safety of add on low-dose mirtazapine in depression

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1085970

21 January 2018

Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1085970

21 January 2018

Combination antidepressant therapy for major depressive disorder: speed and probability of remission

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1085970

21 January 2018

Pharmacokinetics and efficacy of fluvoxamine and amitriptyline in depression.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1085970

21 January 2018

Controlled trial of trimipramine, monoamine oxidase inhibitors, and combined treatment in depressed outpatients

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1085970

21 January 2018

A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1085970

21 January 2018

Safety and tolerability of antipsychotic-mood stabilizer co-treatment in the management of acute bipolar disorder: results from a systematic review and exploratory meta-analysis

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1085970

21 January 2018

The Serotonin Syndrome

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1085970

21 January 2018

A venlafaxine and mirtazapine-induced serotonin syndrome confirmed by de- and re-challenge.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1085970

21 January 2018

Serotonin toxicity: a short review of the literature and two case reports involving citalopram.

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1085970

21 January 2018

Antidepressants: Clinically Relevant Drug Interactions to Be Considered

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1085970

21 January 2018

Clinically relevant pharmacokinetic interaction between venlafaxine and bupropion: a case series

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1085970

21 January 2018

A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1085970

21 January 2018

Mirtazapine in combination with amitriptyline: a drug-drug interaction study in healthy subjects

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1085970

21 January 2018

Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1085970

21 January 2018

Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1085970

21 January 2018

Antidepressant treatment response is modulated by genetic and environmental factors and their interactions

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2015.1085970

21 January 2018

Identifiers

10.1517/14740338.2015.1085970

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38584890&oldid=1768704548"